您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
B7-1/CD80 Fc Chimera Protein, Mouse

B7-1/CD80 Fc Chimera Protein, Mouse

货号: UA011080
价格: 800
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Mouse
  • 分子别名

    B7,B7.1,BB1,CD28LG,CD28LG1,LAB7
  • Accession

    Q00609-1
  • 表达序列

    Val38-Lys245 with Human IgG1 Fc at the C-Terminus

  • 表达宿主

    HEK293
  • 分子量

    70-90kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE, RP-HPLC&SEC-HPLC
  • 内毒素含量

    <0.1EU/μg
  • 活性

    Immobilized B7-1/CD80 Fc Chimera Protein, Mouse(Cat. No. UA011080) at 2.0μg/mL (100μL/well) can bind Biotinylated CTLA-4/CD152 Fc Chimera, Mouse with EC50 of 4.09-6.46ng/mL.
  • 标记

    Unconjugated
  • 标签

    Human IgG1 Fc
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4, 5% trehalose
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
  • 文献引用

    1.Carin C. Stamper, Yan Zhang, James F. Tobin,David V. Erbe, Shinji Ikemizu, Simon J. Davis, Mark L. Stahl, Jasbir Seehra,William S. Somers & Lidia Mosyak: Crystal structure of the B7-1/CTLA-4complex that inhibits human immune responses, Nature volume 410, pages608–611 (2001).

  • 稀释度

背景介绍
  • CD80, the first identified member of the B7 family, is a protein that is widely expressed across a variety of tissues and is also found on some malignant tumor cells. This distribution suggests a potential mechanism by which tumor cells can evade the immune system. Recognized as a potent costimulatory molecule, CD80 plays a significant role in how immune cells regulate malignant growth.
    CD80 is upregulated in response to cellular stress and is essential for effective immune surveillance, particularly during the process of carcinogenesis. Studies have reported that a low surface expression of CD80 on colon carcinoma cells can be an immune evasion mechanism. Conversely, in colorectal cancers (CRC) with high-frequency microsatellite instability (MSI), a subtype known for its immunogenicity and association with better prognosis, CD80 expression is often increased.
    Both in vivo and in vitro research has demonstrated that increased CD80 expression on the surface of tumor cells can effectively activate antitumor immune responses. However, during tumor progression, the expression of CD80 is frequently diminished, possibly due to selective pressures exerted by the immune system.
    Given these findings, enhancing CD80 expression in tumors is a strategy that urgently needs to be explored for the development of effective cancer immunotherapies.

  • 电泳JSON

    • 1μg (R: reducing condition, N: non-reducing condition).

  • 体积排阻色谱JSON(SEC-HPLC)

    • The purity of B7-1/CD80 Fc Chimera Protein, Mouse is more than 95% determined by SEC-HPLC.

  • 反相高效液相色谱JSON(RP-HPLC)

    • The purity of B7-1/CD80 Fc Chimera Protein, Mouse is more than 95% determined by RP-HPLC.

  • ELISA

    • Immobilized B7-1/CD80 Fc Chimera Protein, Mouse (Cat. No. UA011080) at 2.0μg/mL (100μL/well) can bind Biotinylated CTLA-4/CD152 Fc Chimera, Mouse with EC50 of 4.09-6.46ng/mL.

    • Immobilized CTLA-4/CD152 His Tag Protein, Rat (Cat. No. UA010792) at 2.0μg/mL (100μL/well) can bind B7-1/CD80 Fc Chimera Protein, Mouse (Cat. No. UA011080)  with EC50 of 1.36-1.57ng/mL.